Remove Biotech Remove Capital Remove Competitive
article thumbnail

Top 10 countries attracting international tech talent

CIO

These countries offer competitive salaries, a lower cost of living compared to other major tech hubs, and better opportunities for quality of life and work-life balance. As the capital city of the United States, Washington, D.C., Tech talent makes up just over 15% of total tech employment in Ottawa, compared to 11.6%

Startups 516
article thumbnail

Slow Start to Venture Capital Funding in 2024

Alpha Sense BI

The venture capital landscape continues to test the discipline and diligence of investors and startups alike. Like many other asset classes, venture capital continues to be impacted by lingering macroeconomic factors affecting funding and liquidity prospects. Interest rates are high.

Capital 69
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top IPOs to Watch in 2025 | APAC Region

Alpha Sense BI

The firm has been publicly traded in Shanghai since 2000, and this would be Hengruis first major capital raise in over two decades. With a 5,500 member R&D team and 14 research centers, Hengrui has positioned itself as a global leader in biotech innovation, making this one of the most significant healthcare IPOs in APACs 2025 market.

article thumbnail

Venture Capital Trends and Outlook for 2024

Alpha Sense BI

Heading into the second half of 2024, venture capital investors remain cautious as they acknowledge persistent challenging dynamics in the landscape. While dry powder reserves have reached record highs, investors are wary about deploying capital with certain recent macroeconomic factors still fresh in mind.

Capital 52
article thumbnail

Key Takeaways from J.P. Morgan’s 41st Annual Healthcare Conference?

Alpha Sense BI

Attracting industry leaders, emerging fast-growth companies, and technology creators from around the world, life science corporations share their latest advances, leading research, and best practices — as well as their intentions to scale their digital health solutions — to the masses in hopes of securing capital.

Biotech 96
article thumbnail

M&A Trends and Outlook for 2023

Alpha Sense BI

2023 so far has revealed ideal conditions for dealmaking due to valuation resets, lessened competition for deals, and new assets coming to market. Around the world, investors are favoring companies that have proven their profitability and that can demonstrate how they have successfully utilized their capital.

Biotech 97
article thumbnail

M&A in Healthcare: 2024 Outlook

Alpha Sense BI

billion acquisition of Carmot Therapeutics, a clinical-stage biotechnology company with three GLP-1 assets in clinical production, including its CT-388 lead GLP-1 asset, in the hopes of gaining a competitive footing among Novo Nordisk and Eli Lilly’s products currently on the market (Ozempic, Wegovy, and Mounjaro, respectively).